Literature DB >> 2966666

Cyclosporin A metabolites suppress T-cell proliferation by concanavalin A and in a mixed lymphocyte reaction.

M Abecassis1, P Y Wong, N Mason, F Cheung, A V Mee, E H Cole, B Langer, Z Cohen, G A Levy.   

Abstract

To ascertain if cyclosporine metabolites (CMs) have immunosuppressive activity, bile, whole blood and urine taken from patients after cholecystectomy and from a liver transplant recipient on cyclosporin A (CsA) were assayed to determine their effect on T-cell proliferation induced by concanavalin A (Con A) and in a two-way mixed-lymphocyte response. Bile and whole blood from the liver transplant patient completely suppressed Con A proliferation and the mixed lymphocyte response (MLR) at dilutions at which normal bile and whole blood have no suppressive activity, but no such activity was noted from the urine. The CMs were separated into six peaks (fractions) by high-pressure liquid chromatography (HPLC). Metabolites were identified by internal standards and HPLC/mass spectrophotometric analysis. Cyclosporine metabolite fractions 2 and 3 from bile and blood had immunosuppressive activity similar to parent CsA whereas fractions 5 and 6 demonstrated less but substantial immunosuppressive activity. Fractions 2, 3 and 5 demonstrated an ability to inhibit two-way MLR similar to parent CsA; the other metabolite fractions were able to inhibit the MLR but to a lesser extent. These results demonstrate that a number of CMs have immunosuppressive effects similar to those of the parent compound, and this may account for the lack of correlation between whole blood CsA levels and immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966666

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  2 in total

1.  Canadian surgery and the Canadian Journal of Surgery--decades of change.

Authors:  Nis Schmidt
Journal:  Can J Surg       Date:  2007-10       Impact factor: 2.089

Review 2.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.